Company news
Clarity Pharmaceuticals Ltd. (ASX:CU6) news
Clarity Pharmaceuticals Ltd. news releases on 6ix. Latest, Jul 4, 2023: Positive Guidance from FDA on Phase 3 Prostate Cancer Trial
Press releases — page 3
Positive Guidance from FDA on Phase 3 Prostate Cancer Trial
July 3, 2023
Clarity Establishes US Center of Excellence for Research
June 27, 2023
Northstar Achieves Key Production Milestones
June 26, 2023
COMBAT theranostic prostate cancer trial commences in the US
June 19, 2023
Clarity expands supply of Cu-64 for Phase III trials
June 13, 2023
Presentation at Jefferies Healthcare Conference
June 12, 2023
Recruitment complete for Phase II prostate cancer trial
June 6, 2023
Theranostic prostate cancer trial advances to cohort 2
May 24, 2023
Clarity Receives $6.7 million R&D Tax Incentive Refund
April 18, 2023
Clarity Corporate Presentation
March 13, 2023
50% recruitment milestone for NET diagnostic Phase II trial
February 15, 2023
PROPELLER Trial Results
February 13, 2023
Diagnostic prostate cancer trial reaches recruitment target
February 8, 2023
Positive topline results from SAR-bisPSMA diagnostic trial
December 13, 2022
Managing Directors Presentation to AGM
November 23, 2022
IND approval from the FDA for theranostic SAR-Bombesin trial
November 20, 2022
Clarity Presentation -Bell Potter Healthcare Conference 2022
November 9, 2022
50% recruitment reached for Phase II prostate cancer trial
November 1, 2022
Corporate Presentation - Wilsons Drug and Device Conference
October 28, 2022
50% recruitment milestone reached for prostate cancer trial
October 26, 2022
First patient treated in therapeutic prostate cancer trial
October 6, 2022
First participant imaged in Phase II SAR-Bombesin trial
October 5, 2022
First participants imaged in SAR-Bombesin trial
September 13, 2022
Recruitment opens for Phase II trial in Prostate Cancer
September 4, 2022
Paediatric neuroblastoma trial advances to cohort 3
August 23, 2022
Imaging trial in prostate cancer opens for recruitment
August 22, 2022
Clarity Pharmaceuticals : Application for quotation of securities - CU6
July 5, 2022
Clarity Pharmaceuticals : Governance & Trading Policy Update
June 8, 2022
IND Approval by US FDA for Phase II SAR-Bombesin trial
June 5, 2022
Clarity Pharmaceuticals : Notification regarding unquoted securities - CU6
June 1, 2022
Presentation Jefferies Biotech Summit
May 27, 2022
First patient treated in the prostate cancer imaging trial
April 21, 2022
Clarity Half Yearly Report
February 28, 2022
Update on China Grand Pharmaceutical and Healthcare Holdings
February 27, 2022
First patient treated in cohort 2 neuroblastoma trial
February 24, 2022
US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA
February 6, 2022
Clarity receives $3.26 million R&D tax incentive refund
February 3, 2022
SARTATE Neuroblastoma trial advances to cohort 2
January 31, 2022
Managing Directors Presentation to Annual General Meeting
November 24, 2021
Quarterly Activity Report
November 18, 2021
Dosimetry Recruitment of theranostic prostate trial complete
November 9, 2021
Appendix 4C Cash Flow Report
October 26, 2021
Recruitment closed on C-BOBCAT SAR-Bombesin trial
October 18, 2021
App 4E Preliminary Final Report 30 June 2021
August 25, 2021